These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28361188)

  • 21. Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma.
    Kishikawa T; Suzuki M; Takemoto N; Fukusumi T; Michiba T; Hanamoto A; Tanaka H; Tatsumi M; Isohashi F; Seo Y; Tamari K; Ogawa K; Inohara H
    Head Neck; 2021 Apr; 43(4):1184-1193. PubMed ID: 33368784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
    Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease.
    Gámez-Cenzano C; Pino-Sorroche F
    PET Clin; 2014 Apr; 9(2):117-27. PubMed ID: 25030277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
    Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
    J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
    Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I
    Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
    Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of treatment response using PET.
    Basu S; Kumar R; Ranade R
    PET Clin; 2015 Jan; 10(1):9-26. PubMed ID: 25455877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
    Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
    J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early
    Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
    Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
    Öztürk H
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
    Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
    J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.
    Pinker K; Riedl CC; Ong L; Jochelson M; Ulaner GA; McArthur H; Dickler M; Gönen M; Weber WA
    J Nucl Med; 2016 Jul; 57(7):1102-4. PubMed ID: 26985059
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Humbert O; Cadour N; Paquet M; Schiappa R; Poudenx M; Chardin D; Borchiellini D; Benisvy D; Ouvrier MJ; Zwarthoed C; Schiazza A; Ilie M; Ghalloussi H; Koulibaly PM; Darcourt J; Otto J
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1158-1167. PubMed ID: 31760467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?
    Rendl G; Schweighofer-Zwink G; Sorko S; Gallowitsch HJ; Hitzl W; Reisinger D; Pirich C
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Maruyama M; Minami T; Yokoi T; Kuribayashi K; Kijima T; Hashimoto M; Hasegawa S; Yamakado K
    Nucl Med Commun; 2020 Aug; 41(8):790-799. PubMed ID: 32516245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does PET SUV Harmonization Affect PERCIST Response Classification?
    Quak E; Le Roux PY; Lasnon C; Robin P; Hofman MS; Bourhis D; Callahan J; Binns DS; Desmonts C; Salaun PY; Hicks RJ; Aide N
    J Nucl Med; 2016 Nov; 57(11):1699-1706. PubMed ID: 27283930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study.
    Gupta M; Choudhury PS; Rawal S; Goel HC; Rao SA
    Nucl Med Mol Imaging; 2018 Dec; 52(6):420-429. PubMed ID: 30538773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings.
    Martins EB; Chojniak R; Kowalski LP; Nicolau UR; Lima EN; Bitencourt AG
    PLoS One; 2015; 10(11):e0140009. PubMed ID: 26562784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria.
    Maffione AM; Ferretti A; Chondrogiannis S; Rampin L; Marzola MC; Grassetto G; Capirci C; Colletti PM; Rubello D
    Clin Nucl Med; 2013 Oct; 38(10):795-7. PubMed ID: 24107808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group.
    Price P; Jones T
    Eur J Cancer; 1995 Nov; 31A(12):1924-7. PubMed ID: 8562143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.